Information for health professionals
Moved hospital? Let us know here if you now will be randomising to a new trust
Summary:
This is a multi-centre, open-label, pragmatic, individually randomised, parallel group, superiority trial and economic evaluation to determine the clinical and cost effectiveness of SGA versus TI during IHCA. The trial will be conducted in the acute setting in NHS hospitals throughout the UK.
An internal pilot study will confirm the feasibility of the trial. An integrated economic evaluation will assess the cost-effectiveness of SGA compared with TI.
Trial Objectives
(1) Conduct an internal pilot study to confirm the feasibility of the large-scale multi-centre trial
(2) Determine the clinical effectiveness of SGA management, for adults with in-hospital cardiac arrest, in terms of survival with a favourable functional outcome and health-related quality of life.
(3) Estimate, in an integrated economic evaluation, the cost-effectiveness of SGA compared with TI
Trial Outcomes
Primary
Functional status at hospital discharge (or 30 days post-randomisation whichever is shorter) as measured by the modified Rankin Scale (mRS)
Secondary
- Initial ventilation success
- Regurgitation/aspiration during resuscitation
- Return of Spontaneous circulation (ROSC) >20 minutes
- ICU and hospital length of stay
- Health-related quality of life at discharge, 3 and 6 months)
- Survival to hospital discharge, 3 months and 6 months
- Functional status (mRS) at 3 and 6 months
Eligibility Criteria:
Inclusion Criteria |
Exclusion Criteria |
|
|
Contact Trial Team
Email:
Address:
AIRWAYS-3 Trial Manager,
Warwick Clinical Trials Unit,
Warwick Medical School,
University of Warwick,
Coventry.
CV4 7AL
CTU Trial Team Members
Trial Manager - Chloe Norman
Trial Co-ordinator - Jannat Chowdhury
Data Entry Clerk - Laurilee Sprauve